floxuridine has been researched along with Adenocarcinoma, Scirrhous in 9 studies
Floxuridine: An antineoplastic antimetabolite that is metabolized to fluorouracil when administered by rapid injection; when administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate. It has been used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.
floxuridine : A pyrimidine 2'-deoxyribonucleoside compound having 5-fluorouracil as the nucleobase; used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.
Adenocarcinoma, Scirrhous: An adenocarcinoma with a hard (Greek skirrhos, hard) structure owing to the formation of dense connective tissue in the stroma. (From Dorland, 27th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "We evaluated the safety and efficacy of neoadjuvant chemotherapy with docetaxel (TXT), epirubicin (EPI) and doxifluridine (5'-DFUR) in 5 patients with locally advanced breast cancer on an outpatient basis." | 7.72 | [Docetaxel (TXT), epirubicin (EPI) and doxifluridine (5'-DFUR) combination neoadjuvant chemotherapy for outpatients with locally advanced breast cancer]. ( Hamada, K; Kakihara, Y; Kubota, K; Sawada, T; Tagaya, N, 2004) |
| "It is well-known that breast cancer easily metastasizes to the bone, liver, pleura and lymph node, but rarely to the ovarium or peritoneum when chemotherapy is conducted." | 5.33 | [Weekly paclitaxel administration and intraabdominal CBDCA injection possibly beneficial treatment for recurrent breast cancer associated with metastatic ovarian cancer and peritoneal dissemination after operation--a case report]. ( Deguchi, Y; Kamimura, K; Kaneko, I; Kii, E; Murata, T; Nonogaki, H; Tanaka, T; Tsubono, M; Yasumizu, R, 2005) |
| "We evaluated the safety and efficacy of neoadjuvant chemotherapy with docetaxel (TXT), epirubicin (EPI) and doxifluridine (5'-DFUR) in 5 patients with locally advanced breast cancer on an outpatient basis." | 3.72 | [Docetaxel (TXT), epirubicin (EPI) and doxifluridine (5'-DFUR) combination neoadjuvant chemotherapy for outpatients with locally advanced breast cancer]. ( Hamada, K; Kakihara, Y; Kubota, K; Sawada, T; Tagaya, N, 2004) |
| "It is well-known that breast cancer easily metastasizes to the bone, liver, pleura and lymph node, but rarely to the ovarium or peritoneum when chemotherapy is conducted." | 1.33 | [Weekly paclitaxel administration and intraabdominal CBDCA injection possibly beneficial treatment for recurrent breast cancer associated with metastatic ovarian cancer and peritoneal dissemination after operation--a case report]. ( Deguchi, Y; Kamimura, K; Kaneko, I; Kii, E; Murata, T; Nonogaki, H; Tanaka, T; Tsubono, M; Yasumizu, R, 2005) |
| "We report a case of breast cancer with spinal and vertebral lesions." | 1.32 | [Successful combination therapy with 5'-DFUR and MPA for breast cancer with spinal and vertebral metastases]. ( Hashiguchi, H; Hirooka, Y; Kamasako, A; Nozaka, K; Ohgami, Y; Otani, S; Takebayashi, M; Tanida, O; Toyota, N; Wakatsuki, T, 2004) |
| "Higher TP expression was observed in ovarian cancers than in normal ovaries." | 1.32 | [Significance of tissue thymidine phosphorylase and dihydropyrimidine dehydrogenase activities in ovarian cancer]. ( Akimoto, T; Hasegawa, K; Kishimoto, Y; Morimoto, Y; Sawai, T, 2004) |
| " Two months later a side effect of MPA, her body weight gain, was observed, and the dosage of MPA was reduced from 1,200 mg/day to 800 mg/day." | 1.31 | [A case of long surviving advanced recurrent breast cancer with multiple bone metastases responding to treatment with 5'-DFUR combined with MPA]. ( Otsuka, T; Tashiro, S; Terashima, Y, 2002) |
| "A 55-year-old woman with recurrent breast cancer treated with sequential mastectomies, chemo-and hormonal therapy of UFT, CPM and TAM, achieved remission." | 1.29 | [A case of recurrent breast cancer responding to long-term treatment with 5'-DFUR combined with MPA]. ( Kimura, M; Koida, T; Sekihara, M, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (11.11) | 18.7374 |
| 1990's | 2 (22.22) | 18.2507 |
| 2000's | 6 (66.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Otani, S | 1 |
| Toyota, N | 1 |
| Nozaka, K | 1 |
| Wakatsuki, T | 1 |
| Takebayashi, M | 1 |
| Kamasako, A | 1 |
| Tanida, O | 1 |
| Hashiguchi, H | 1 |
| Ohgami, Y | 1 |
| Hirooka, Y | 1 |
| Tagaya, N | 1 |
| Kakihara, Y | 1 |
| Hamada, K | 1 |
| Sawada, T | 1 |
| Kubota, K | 1 |
| Morimoto, Y | 1 |
| Hasegawa, K | 1 |
| Sawai, T | 1 |
| Kishimoto, Y | 1 |
| Akimoto, T | 1 |
| Tsubono, M | 1 |
| Kaneko, I | 1 |
| Kii, E | 1 |
| Tanaka, T | 1 |
| Murata, T | 1 |
| Kamimura, K | 1 |
| Deguchi, Y | 1 |
| Nonogaki, H | 1 |
| Yasumizu, R | 1 |
| Fukuda, Y | 1 |
| Fujio, N | 1 |
| Ihara, T | 1 |
| Takatori, H | 1 |
| Tsukazaki, T | 1 |
| Koyama, I | 1 |
| Tsukazaki, Y | 1 |
| Osugi, H | 1 |
| Kimura, M | 1 |
| Koida, T | 1 |
| Sekihara, M | 1 |
| Kihara, M | 1 |
| Matsusaka, K | 1 |
| Miyauchi, A | 1 |
| Maeda, M | 1 |
| Otsuka, T | 1 |
| Terashima, Y | 1 |
| Tashiro, S | 1 |
| Enomoto, T | 1 |
| Watanabe, A | 1 |
9 other studies available for floxuridine and Adenocarcinoma, Scirrhous
| Article | Year |
|---|---|
[Successful combination therapy with 5'-DFUR and MPA for breast cancer with spinal and vertebral metastases].
Topics: Adenocarcinoma, Scirrhous; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combine | 2004 |
[Docetaxel (TXT), epirubicin (EPI) and doxifluridine (5'-DFUR) combination neoadjuvant chemotherapy for outpatients with locally advanced breast cancer].
Topics: Adenocarcinoma, Scirrhous; Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protoc | 2004 |
[Significance of tissue thymidine phosphorylase and dihydropyrimidine dehydrogenase activities in ovarian cancer].
Topics: 5'-Nucleotidase; Adenocarcinoma, Scirrhous; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineo | 2004 |
[Weekly paclitaxel administration and intraabdominal CBDCA injection possibly beneficial treatment for recurrent breast cancer associated with metastatic ovarian cancer and peritoneal dissemination after operation--a case report].
Topics: Adenocarcinoma, Scirrhous; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neopl | 2005 |
[A case of advanced gastric cancer with direct invasion of the transverse colon responding to paclitaxel/5'-DFUR combined therapy].
Topics: Adenocarcinoma, Scirrhous; Antineoplastic Combined Chemotherapy Protocols; Colon, Transverse; Coloni | 2005 |
[A case of recurrent breast cancer responding to long-term treatment with 5'-DFUR combined with MPA].
Topics: Adenocarcinoma, Scirrhous; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Ad | 1996 |
[A case of stage IV breast cancer showing long-term complete response to combination therapy with 5'-DFUR and MPA].
Topics: Adenocarcinoma, Scirrhous; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Ne | 1998 |
[A case of long surviving advanced recurrent breast cancer with multiple bone metastases responding to treatment with 5'-DFUR combined with MPA].
Topics: Adenocarcinoma, Scirrhous; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Bre | 2002 |
[Effect of combination chemotherapy of 5'-DFUR, cyclophosphamide and tamoxifen in a case of advanced breast cancer].
Topics: Adenocarcinoma, Scirrhous; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; C | 1989 |